文献速递淋巴瘤

早期膈下霍奇金淋巴瘤患者的结局:德国霍奇金研究组的综合分析

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
PubMed 文献 · J Clin Oncol · 2018-07-10

在HD13和HD14试验的2903例早期霍奇金淋巴瘤患者中,223例(7.7%)为孤立性膈下淋巴结病变,其中位随访51个月后5年无进展生存率和总生存率分别为80.1%和91.5%,均显著低于膈上病变组的91.2%和97.6%;多因素分析显示膈下病变是无进展生存率(HR 1.5)和总生存率(HR 2.0)的显著风险因素,但接受较强化疗方案的患者中未观察到不良结局。

要点

  • 孤立性膈下病变占早期霍奇金淋巴瘤的7.7%,患者年龄较大、体能状态较差、男性更多、结节硬化型较少。
  • 膈下病变组5年无进展生存率和总生存率分别为80.1%和91.5%,均显著低于膈上病变组的91.2%和97.6%。
  • 多因素分析中膈下病变是无进展生存率(HR 1.5)和总生存率(HR 2.0)的显著风险因素,但较强化疗可抵消不良结局。

核心结论

  • 仅表现为膈下病变的早期霍奇金淋巴瘤是一个独特患者群体,结局较差,但适当的联合模式治疗可抵消这一不良结局。

研究设计与样本

  • 对德国霍奇金研究组HD13(ISRCTN63474366)和HD14(ISRCTN04761296)试验中2903例合格早期霍奇金淋巴瘤患者进行风险因素分析,比较膈下与膈上病变患者的特征和结局。

主要发现

  • 2903例合格患者中223例(7.7%)诊断为孤立性膈下淋巴结病变。
  • 中位随访51个月后,膈下病变组5年无进展生存率和总生存率分别为80.1%和91.5%,膈上病变组分别为91.2%和97.6%,差异均显著(各P < .001)。
  • 多因素分析中,膈下霍奇金淋巴瘤仍是无进展生存率(HR 1.5;95% CI 1.04至2.2;P = .03)和总生存率(HR 2.0;95% CI 1.2至3.5;P = .01)的显著风险因素。
  • 在HD13中接受2周期ABVD、在HD14中接受2周期BEACOPPescalated加2周期ABVD(所有患者均接受30 Gy累及野放疗)的较强化疗患者中,未观察到无进展生存率和总生存率较差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The prognostic effect of isolated infradiaphragmatic involvement in Hodgkin lymphoma (HL) is controversial, and there are little data about patients treated with current therapies. Therefore, we performed a risk factor analysis to focus on isolated nodal infradiaphragmatic disease in patients treated within the German Hodgkin Study Group trials HD13 (clinical trial information: ISRCTN63474366) and HD14 (clinical trial information: ISRCTN04761296) for early-stage HL. Patients and Methods Characteristics and outcomes of patients who had infradiaphragmatic HL were compared with patients who had supradiaphragmatic disease. Progression-free survival (PFS) and overall survival (OS) were estimated according to Kaplan-Meier methods and were compared between groups using the log-rank test and Cox proportional hazards regression, which was also applied for multivariable analyses that adjusted for relevant baseline characteristics. Results Of 2,903 qualified patients, 223 (7.7%) were diagnosed with isolated nodal infradiaphragmatic disease. In general, these patients were older, had a poorer performance status, were more often male, and had the nodular sclerosis subtype less often than those with supradiaphragmatic disease. After a median follow-up time of 51 months, PFS and OS were significantly worse in patients with infradiaphragmatic disease (5-year PFS and OS, 80.1% and 91.5% v 91.2% and 97.6% in patients with supradiaphragmatic disease; each P < .001). In multivariable analyses, infradiaphragmatic HL remained a significant risk factor in terms of PFS (hazard ratio [HR], 1.5; 95% CI, 1.04 to 2.2; P = .03) and OS (HR, 2.0; 95% CI, 1.2 to 3.5; P = .01). However, inferior PFS and OS could not be observed among those patients treated with the more intensive chemotherapy (two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD] in HD13, and two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPPescalated] plus two cycles of ABVD in HD14; all patients received 30 Gy of involved-field radiotherapy). Conclusion Early-stage HL that presents with infradiaphragmatic disease only represents a distinct patient group with an inferior outcome. However, this adverse outcome can be outweighed by appropriate combined modality treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sasse S, Goergen H, Plütschow A, et al. Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol. 2018. PMID: 29989855. doi:10.1200/JCO.2018.78.7192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。